The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis.

Gaucher disease MGUS TiDiS theory bone microenvironment endosteal niche disruption multiple myeloma osteoblasts osteoclasts

Journal

Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988

Informations de publication

Date de publication:
12 Jul 2023
Historique:
received: 30 05 2023
revised: 30 06 2023
accepted: 10 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Multiple Myeloma (MM) and its preexisting stage, termed Monoclonal Gammopathy of Undetermined Significance (MGUS), have long been considered mainly as genomic diseases. However, the bone changes observed in both conditions have led to a reassessment of the role of the bone microenvironment, mainly the endosteal niche in their genesis. Here, we consider the disruption of the endosteal niche in the bone marrow, that is, the shift of the endosteal niche from an osteoblastic to an osteoclastic profile produced by bone senescence and inflammaging, as the key element. Thus, this disrupted endosteal niche is proposed to represent the permissive microenvironment necessary not only for the emergence of MM from MGUS but also for the emergence and maintenance of MGUS. Moreover, the excess of osteoclasts would favor the presentation of antigens (Ag) into the endosteal niche because osteoclasts are Ag-presenting cells. As such, they could significantly stimulate the presentation of some specific Ag and the clonal expansion of the stimulated cells as well as favor the expansion of such selected clones because osteoclasts are immunosuppressive. We also discuss this scenario in the Gaucher disease, in which the high incidence of MGUS and MM makes it a good model both at the bone level and the immunological level. Finally, we envisage that this endosteal niche disruption would increase the stochasticity (epigenetic and genetic instability) in the selected clones, according to our Tissue Disruption-induced cell Stochasticity (TiDiS) theory.

Identifiants

pubmed: 37508420
pii: biology12070990
doi: 10.3390/biology12070990
pmc: PMC10376322
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Immunol Rev. 2019 May;289(1):142-157
pubmed: 30977190
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Blood. 2004 May 1;103(9):3258-64
pubmed: 14726388
Front Immunol. 2019 Apr 24;10:788
pubmed: 31068930
Cell Stem Cell. 2019 Sep 5;25(3):407-418.e6
pubmed: 31303548
Stem Cell Reports. 2020 Aug 11;15(2):317-325
pubmed: 32649902
Front Immunol. 2016 Nov 14;7:502
pubmed: 27895645
Bone. 2019 Feb;119:1-7
pubmed: 30010082
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759688
Cell Stem Cell. 2015 Mar 5;16(3):254-67
pubmed: 25748932
Bone Res. 2023 Mar 14;11(1):15
pubmed: 36918531
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669929
Front Endocrinol (Lausanne). 2022 Jul 22;13:885879
pubmed: 35937818
J Immunol Res. 2015;2015:192761
pubmed: 26064996
J Cell Biochem. 2010 Dec 1;111(5):1138-48
pubmed: 20683902
Front Immunol. 2021 Apr 15;12:658535
pubmed: 33936091
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 35104801
Blood. 2003 May 15;101(10):4137-9
pubmed: 12531815
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435306
Int J Mol Sci. 2020 May 23;21(10):
pubmed: 32456199
Cell Rep. 2019 Dec 3;29(10):3313-3330.e4
pubmed: 31801092
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
J Bone Oncol. 2018 Sep 15;13:62-70
pubmed: 30591859
J Bone Miner Res. 2014 Dec;29(12):2529-33
pubmed: 25319751
Nat Commun. 2015 Dec 03;6:8983
pubmed: 26632274
Cell Stem Cell. 2017 Jun 1;20(6):771-784.e6
pubmed: 28330582
Blood. 2013 Sep 5;122(10):1730-40
pubmed: 23814020
Crit Rev Oncol Hematol. 2022 Apr;172:103640
pubmed: 35183697
Nat Rev Endocrinol. 2015 Sep;11(9):513-21
pubmed: 26032105
Blood. 2002 Dec 15;100(13):4615-21
pubmed: 12393684
Front Immunol. 2018 Aug 10;9:1822
pubmed: 30147691
Front Oncol. 2018 Sep 10;8:355
pubmed: 30250824
Mol Genet Metab. 2020 Apr;129(4):286-291
pubmed: 32044242
N Engl J Med. 2016 Feb 11;374(6):555-61
pubmed: 26863356
Nat Med. 2003 Sep;9(9):1151-7
pubmed: 12910264
Blood. 1996 Jun 1;87(11):4762-9
pubmed: 8639847
J Exp Med. 2005 Jun 6;201(11):1781-91
pubmed: 15928197
Am J Hematol. 2022 Oct;97(10):1337-1347
pubmed: 36054609
Int J Mol Sci. 2022 Feb 04;23(3):
pubmed: 35163708
Front Immunol. 2019 Jun 19;10:1408
pubmed: 31275328
Am J Pathol. 2004 Apr;164(4):1399-406
pubmed: 15039227
JBMR Plus. 2021 Apr 02;5(4):e10488
pubmed: 33869998
Nature. 2016 Apr 21;532(7599):323-8
pubmed: 27074509
Cells. 2021 Feb 19;10(2):
pubmed: 33669483
Leuk Lymphoma. 1998 Dec;32(1-2):121-7
pubmed: 10037007
Front Aging. 2020 Oct 15;1:602108
pubmed: 35822168
Blood Adv. 2022 Nov 22;6(22):5873-5883
pubmed: 35977111
Front Immunol. 2017 Oct 19;8:1347
pubmed: 29098000
Lancet. 1974 Nov 23;2(7891):1230-3
pubmed: 4139472
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6995-7004
pubmed: 30894483
Front Immunol. 2021 Nov 11;12:738204
pubmed: 34858399
Blood. 2014 Apr 3;123(14):2204-8
pubmed: 24425802
Nat Rev Mol Cell Biol. 2021 Feb;22(2):75-95
pubmed: 33328614
Front Endocrinol (Lausanne). 2019 May 14;10:285
pubmed: 31139147
J Clin Oncol. 1989 Dec;7(12):1909-14
pubmed: 2585025
Front Cell Dev Biol. 2022 Feb 09;10:841612
pubmed: 35223858

Auteurs

Jean-Pascal Capp (JP)

Toulouse Biotechnology Institute, INSA/University of Toulouse, CNRS, INRAE, 31077 Toulouse, France.

Régis Bataille (R)

School of Medicine, University of Angers, 49045 Angers, France.

Classifications MeSH